$894 Million is the total value of Bain Capital Life Sciences Investors, LLC's 31 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 3.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVALENT INC | $164,446,964 | +9.0% | 3,577,267 | 0.0% | 18.39% | +18.4% | ||
| PHVS | Sell | PHARVARIS N V | $99,856,146 | +35.5% | 4,784,674 | -1.7% | 11.17% | +47.1% |
| NEWAMSTERDAM PHARMA COMPANYordinary shares | $96,883,695 | -22.2% | 10,473,913 | 0.0% | 10.83% | -15.5% | ||
| SWTX | SPRINGWORKS THERAPEUTICS INC | $71,239,818 | -11.8% | 3,081,307 | 0.0% | 7.97% | -4.3% | |
| Sell | DISC MEDICINE INC | $62,602,964 | +5.8% | 1,332,545 | -0.0% | 7.00% | +14.9% | |
| SVRA | Buy | SAVARA INC | $53,799,799 | +44.9% | 14,232,751 | +22.5% | 6.02% | +57.3% |
| CRNX | Sell | CRINETICS PHARMACEUTICALS IN | $37,934,916 | -8.7% | 1,275,552 | -44.7% | 4.24% | -0.9% |
| Buy | TANGO THERAPEUTICS INC | $32,571,385 | +410.5% | 2,892,663 | +50.5% | 3.64% | +454.3% | |
| NTRA | NATERA INC | $30,983,717 | -9.1% | 700,197 | 0.0% | 3.46% | -1.3% | |
| CABA | CABALETTA BIO INC | $30,440,000 | +17.9% | 2,000,000 | 0.0% | 3.40% | +28.0% | |
| ACRS | ACLARIS THERAPEUTICS INC | $23,290,000 | -33.9% | 3,400,000 | 0.0% | 2.60% | -28.3% | |
| EQRX INC | $22,207,932 | +19.4% | 10,003,573 | 0.0% | 2.48% | +29.6% | ||
| XFOR | X4 PHARMACEUTICALS INC | $17,397,041 | -43.8% | 15,960,588 | 0.0% | 1.94% | -39.0% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $15,930,000 | -44.3% | 3,000,000 | 0.0% | 1.78% | -39.5% | |
| NRIX | NURIX THERAPEUTICS INC | $14,327,860 | -21.3% | 1,822,883 | 0.0% | 1.60% | -14.6% | |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $13,627,278 | -50.2% | 913,969 | -63.4% | 1.52% | -45.9% |
| DVAX | Sell | DYNAVAX TECHNOLOGIES CORP | $13,514,550 | -56.7% | 915,000 | -62.1% | 1.51% | -53.0% |
| ANNX | ANNEXON INC | $13,456,545 | -33.0% | 5,701,926 | 0.0% | 1.50% | -27.2% | |
| MARINUS PHARMACEUTICALS INC | $11,520,017 | -25.9% | 1,431,058 | 0.0% | 1.29% | -19.6% | ||
| MRSN | MERSANA THERAPEUTICS INC | $11,002,865 | -61.4% | 8,663,673 | 0.0% | 1.23% | -58.1% | |
| RAPID MICRO BIOSYSTEMS INC | $9,109,325 | +8.0% | 8,434,560 | 0.0% | 1.02% | +17.3% | ||
| SYROS PHARMACEUTICALS INC | $8,392,541 | +25.4% | 2,124,694 | 0.0% | 0.94% | +36.3% | ||
| SOLID BIOSCIENCES INC | $7,888,663 | -51.9% | 3,130,422 | 0.0% | 0.88% | -47.8% | ||
| AVIR | ATEA PHARMACEUTICALS INC | $7,456,914 | -19.8% | 2,485,638 | 0.0% | 0.83% | -12.9% | |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $6,320,000 | -18.3% | 2,000,000 | 0.0% | 0.71% | -11.3% | |
| XILIO THERAPEUTICS INC | $5,919,421 | -19.5% | 2,805,413 | 0.0% | 0.66% | -12.5% | ||
| 2SEVENTY BIO INC | $5,522,892 | -61.3% | 1,408,901 | 0.0% | 0.62% | -57.9% | ||
| INVIVYD INC | $3,293,252 | +61.9% | 1,937,207 | 0.0% | 0.37% | +76.1% | ||
| CCCC | C4 THERAPEUTICS INC | $3,054,511 | -32.4% | 1,642,210 | 0.0% | 0.34% | -26.5% | |
| NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $190,000 | -9.1% | 100,000 | 0.0% | 0.02% | -4.5% | ||
| CARA | Sell | CARA THERAPEUTICS INC | $39,725 | -98.5% | 23,646 | -97.5% | 0.00% | -98.5% |
| Exit | THIRD HARMONIC BIO INC | $0 | – | -640,631 | -100.0% | -0.32% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCLS II Investco (GP), LLC #6
- BCLS II Investco, LP #7
- Bain Capital Life Sciences III General Partner, LLC #8
- Bain Capital Life Sciences Fund III, L.P. #9
- Bain Capital Life Sciences Opportunities III GP, LLC #10
- Bain Capital Life Sciences Opportunities III, LP #11
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.